193 Results for "

LSD1

" in MedChemExpress (MCE) Product Catalog:
Products (193)

193 Results for "LSD1" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-16012
CAS No.: 1186222-89-8
Synonyms: 4SC-202
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

Domatinostat tosylate (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-16012A
CAS No.: 910462-43-0
Synonyms: 4SC-202 free base
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

Domatinostat (4SC-202 free base) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-103085
CAS No.: 1422535-52-1
Purity:  99.13%
Target:  

Histone Demethylase

Research Areas:  

Cancer

T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase (LSD1) inhibitor with an IC50 value of 2.1 nM.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-117226A
CAS No.: 2436760-79-9
Purity:  98.58%
Target:  

Histone Demethylase

Research Areas:  

Others

GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a Kd value of 9 nM and a biochemical IC50 of 37 nM.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15313C
CAS No.: 2070015-03-9
Purity:  97.08%
Target:  

Histone Demethylase

Research Areas:  

Metabolic Disease Cancer

CBB1007 trihydrochloride is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 trihydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 trihydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 trihydrochloride is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma [1] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-112623
CAS No.: 1357362-02-7
Purity:  99.53%
Synonyms: ORY-2001
Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor [1].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19333
CAS No.: 1357302-64-7
Research Areas:  

Infection

OG-L002 is a potent and highly selective LSD1 inhibitor with an IC50 of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC50s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes [1].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-138830
CAS No.: 1818252-53-7
Purity:  99.81%
Target:  

Histone Demethylase

Research Areas:  

Neurological Disease

TAK-418 is a selective, orally active LSD1 (KDM1A) enzyme inhibitor with an IC50 of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models [1] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-155115
CAS No.: 2904571-94-2
Purity:  98.88%
Research Areas:  

Cancer

LSD1-IN-27 is an orally active LSD1 inhibitor (IC50: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer [1].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-169938
CAS No.: 2966782-82-9
Research Areas:  

Cancer

LSD1/HDAC-IN-2 (Compound 20c) is the inhibitor for LSD and HDAC, that inhibits LSD1, HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, with IC50s of 39.0, 1.4, 1.0, 1.3, 2.9 and 16.0 nM, respectively. LSD1/HDAC-IN-2 inhibits the proliferation of cancer cells, especially the colorectal cancer cells. LSD1/HDAC-IN-2 arrests the cell cycle at G2/M phase, inhibits cell migration, and induces apoptosis in HCT-116 and HT-29 cells. LSD1/HDAC-IN-2 exhibits antitumor efficacy in mouse model without significant toxicity [1].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P75551
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KDM1A; [Histone H3]-Dimethyl-L-Lysine(4) FAD-Dependent Demethylase 1A; Prev. AOF2; FAD-Binding Protein BRAF35-HDAC Complex, 110 KDa Subunit; Prev. KDM1; Lysine-Specific Histone Demethylase 1; Lysine-Specific Histone Demethylase 1A; Lysine-Specific Histone
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19612A
CAS No.: 1831167-98-6
Target:  

Histone Demethylase

Research Areas:  

Cancer

DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC50 of 84 nM [1].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-149946
CAS No.: 2716217-79-5
Research Areas:  

Cancer

HDAC-IN-57 is an orally active inhibitor of histone deacetylases (HDAC), with IC50s of 2.07 nM, 4.71 nM, 2.4 nM and 107 nM for HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-57 can inhibits LSD1, with IC50 of 1.34 μΜ. HDAC-IN-57 induces apoptosis, and has anti-tumor activity [1].
loading...
    loading...
Cat. No.: HY-110130
CAS No.: 1781835-13-9
Purity:  99.13%
Target:  

Histone Demethylase

Research Areas:  

Cardiovascular Disease Cancer

RN-1 dihydrochloride is a potent, brain-penetrant, irreversible and selective lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 70 nM. RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC50 values of 0.51 μM and 2.785 μM respectively [1] .
loading...
    loading...
Cat. No.: HY-164099
CAS No.: 2982787-50-6
Research Areas:  

Cancer

LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma [1] .
loading...
    loading...
Cat. No.: HY-176875
Target:  

Molecular Glues

Research Areas:  

Cancer

CoREST/LSD1 degrader-1 (Compound 4) is a molecular glue degrader targeting the KBTBD4 E3 ubiquitin ligase. CoREST/LSD1 degrader-1 is promising for research of KBTBD4-mutant driven cancers (e.g., medulloblastoma) and epigenetic dysregulation disorders [1].
loading...
    loading...
Cat. No.: HY-121095
CAS No.: 1591932-50-1
Target:  

Histone Demethylase

Research Areas:  

Neurological Disease Cancer

Bizine, a Phenelzine analogue, is a potent and selective LSD1 inhibitor, with a b>Ki of 59 nM. Bizine can modulate bulk histone methylation in cancer cells. Bizine shows neuroprotective effects [1].
loading...
    loading...
Cat. No.: HY-178826
LSD1-IN-45 is an LSD1 inhibitor and a ligand for the target protein for PROTAC. LSD1-IN-45 can be used to synthesize PROTAC LD-110 (HY-178825) [1].
loading...
    loading...
Cat. No.: HY-100859
CAS No.: 2035912-55-9
Target:  

Histone Demethylase

Research Areas:  

Cancer

LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 [1].
loading...
    loading...
Cat. No.: HY-100546
CAS No.: 1431368-48-7
Target:  

Histone Demethylase

Research Areas:  

Infection Metabolic Disease Cancer

GSK-LSD1, a chemical probe, is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis [1] .
loading...
    loading...